+

WO2006063418A3 - Dispositif radioactif - Google Patents

Dispositif radioactif Download PDF

Info

Publication number
WO2006063418A3
WO2006063418A3 PCT/BE2005/000185 BE2005000185W WO2006063418A3 WO 2006063418 A3 WO2006063418 A3 WO 2006063418A3 BE 2005000185 W BE2005000185 W BE 2005000185W WO 2006063418 A3 WO2006063418 A3 WO 2006063418A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanostructure
core
radioactive
concerns
radioactif
Prior art date
Application number
PCT/BE2005/000185
Other languages
English (en)
Other versions
WO2006063418A2 (fr
Inventor
Stephane Lucas
Original Assignee
Univ Notre Dame De La Paix
Stephane Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Notre Dame De La Paix, Stephane Lucas filed Critical Univ Notre Dame De La Paix
Priority to EP05846349A priority Critical patent/EP1838354A2/fr
Priority to US11/721,959 priority patent/US20090297437A1/en
Publication of WO2006063418A2 publication Critical patent/WO2006063418A2/fr
Publication of WO2006063418A3 publication Critical patent/WO2006063418A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La présente invention se rapporte à une nanostructure radioactive ou radioactivable comprenant un cœur, ledit cœur comprenant au moins deux atomes dont au moins un est radioactif ou radioactivable, et une enveloppe enrobant ledit cœur et choisie dans un matériau sélectionné de façon telle qu'au maximum 20% du rayonnement radioactif produit par le coeur est arrêté ou absorbé par l'enveloppe. Elle concerne aussi son procédé de fabrication. La présente invention couvre également les différentes utilisations de cette nanostructure, et notamment son utilisation dans le domaine médical, et plus précisément en radiothérapie ciblée.
PCT/BE2005/000185 2004-12-17 2005-12-19 Dispositif radioactif WO2006063418A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05846349A EP1838354A2 (fr) 2004-12-17 2005-12-19 Nanostructure radioactif
US11/721,959 US20090297437A1 (en) 2004-12-17 2005-12-19 Radioactive device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04447284 2004-12-17
EP04447284.3 2004-12-17

Publications (2)

Publication Number Publication Date
WO2006063418A2 WO2006063418A2 (fr) 2006-06-22
WO2006063418A3 true WO2006063418A3 (fr) 2006-10-12

Family

ID=36475456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2005/000185 WO2006063418A2 (fr) 2004-12-17 2005-12-19 Dispositif radioactif

Country Status (3)

Country Link
US (1) US20090297437A1 (fr)
EP (1) EP1838354A2 (fr)
WO (1) WO2006063418A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645085B2 (ja) * 2008-04-24 2014-12-24 ジ オーストラリアン ナショナル ユニバーシティー マクロ分子を放射性標識化するための方法
JP2011518198A (ja) 2008-04-24 2011-06-23 ジ オーストラリアン ナショナル ユニバーシティー 放射性標識合成ポリマーのための方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018020A1 (fr) * 1990-05-17 1991-11-28 Albany Medical College Complexe utilise pour la localisation in-vivo de cibles
EP1162626A1 (fr) * 1999-03-11 2001-12-12 Kansai Technology Licensing Organization Co., Ltd. Microsphere radioactive et procede de fabrication
WO2002062397A2 (fr) * 2001-02-05 2002-08-15 Biophysics Assay Laboratory, Inc. Synthese, compositions et procedes permettant de mesurer la concentration de composes marques par isotope stable et se presentant sous formes biologiques et produits d'excretion de type biologique
WO2004040972A2 (fr) * 2002-11-04 2004-05-21 Biosphere Medical Microspheres d'hydrogels polymeres associees a des radioisotopes et procedes de production et d'utilisation de celles-ci
US20050019257A1 (en) * 2003-07-11 2005-01-27 Chong-Oh Kim Radioactive magnetic fluids for treatment or diagnosis of cancer, process for preparing them and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060036A (en) * 1998-02-09 2000-05-09 Implant Sciences Corporation Radioactive seed implants
WO2005018681A1 (fr) * 2003-06-03 2005-03-03 The Trustees Of The University Of Pennsylvania Produits nano-radio-pharmaceutiques et leurs methodes d'utilisation
US20060239907A1 (en) * 2003-06-03 2006-10-26 The Trustees Of The University Of Pennsylvania Stealthy nano agents
WO2006096206A2 (fr) * 2004-08-18 2006-09-14 Isoray Medical, Inc. Procede de preparation de particules de poudre radioactive renfermant du cesium-131 a utiliser dans des sources de curietherapie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018020A1 (fr) * 1990-05-17 1991-11-28 Albany Medical College Complexe utilise pour la localisation in-vivo de cibles
EP1162626A1 (fr) * 1999-03-11 2001-12-12 Kansai Technology Licensing Organization Co., Ltd. Microsphere radioactive et procede de fabrication
WO2002062397A2 (fr) * 2001-02-05 2002-08-15 Biophysics Assay Laboratory, Inc. Synthese, compositions et procedes permettant de mesurer la concentration de composes marques par isotope stable et se presentant sous formes biologiques et produits d'excretion de type biologique
WO2004040972A2 (fr) * 2002-11-04 2004-05-21 Biosphere Medical Microspheres d'hydrogels polymeres associees a des radioisotopes et procedes de production et d'utilisation de celles-ci
US20050019257A1 (en) * 2003-07-11 2005-01-27 Chong-Oh Kim Radioactive magnetic fluids for treatment or diagnosis of cancer, process for preparing them and use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKASAKA Y ET AL: "Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies", DRUG DESIGN AND DELIVERY 1988 UNITED KINGDOM, vol. 3, no. 1, 1988, pages 85 - 97, XP008067337, ISSN: 0884-2884 *
BORCHARDT ET AL: "Body distribution of 75Se-radiolabeled silica nanoparticles covalently coated with.omega.-functionalized surfactants after intravenous injection in rats", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 2, 1994, pages 61 - 77, XP002083903, ISSN: 1061-186X *
BRANDAU W ET AL: "Nanoporous ceramic coatings for synthesis of radioactive implants", JOURNAL OF NUCLEAR MEDICINE, vol. 41, no. 5 Suppl., May 2000 (2000-05-01), & 47TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE; ST. LOUIS, MISSOURI, US; 03-07 JUIN 2000, pages 244P, ABRÉGÉ NO. 1076, XP002394014, ISSN: 0161-5505 *
DE MARCO G ET AL: "Development and optimization of magnetite-dextran nanoparticles for lymphoscintigraphy by intravenous injection", MEDECINE NUCLEAIRE, vol. 20, no. 1, 1996, pages 6 - 16, XP008067317, ISSN: 0928-1258 *
DENIZOT B: "New perspectives in therapeutic targeting of particulate radiopharmaceuticals", MEDECINE NUCLEAIRE 1995 FRANCE, vol. 19, no. 2-3, 1995, pages 151 - 153, XP008067256, ISSN: 0928-1258 *
HAWLEY ANN E ET AL: "Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers", FEBS LETTERS, vol. 400, no. 3, 1997, pages 319 - 323, XP002394013, ISSN: 0014-5793 *
MOORE A ET AL: "Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages", JOURNAL OF MAGNETIC RESONANCE IMAGING 1997 UNITED STATES, vol. 7, no. 6, 1997, pages 1140 - 1145, XP008067384, ISSN: 1053-1807 *
SCHAEFER V ET AL: "PHAGOCYTOSIS OF NANOPARTICLES BY HUMAN IMMUNODEFICIENCY VIRUS HIV-INFECTED MACROPHAGES A POSSIBILITY FOR ANTIVIRAL DRUG TARGETING", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 9, no. 4, 1992, pages 541 - 546, XP008067257, ISSN: 0724-8741 *
WITTENDORP-RECHENMANN E ET AL: "SUPERPARAMAGNETIC NANOPARTICLES CONTAINING LIPOSOMES AS POTENTIAL SPECIFIC CONTRAST AGENT FOR BRAIN MR IMAGING: INITIAL FEASIBILITY STUDY BY A COMBINED APPROACH WITH 59FE-ACTIVATED TRACK-AUTORADIOGRAPHY", JOURNAL OF TRACE AND MICROPROBE TECHNIQUES, DEKKER, NEW YORK, NY, US, vol. 16, no. 4, 1998, pages 523 - 534, XP008021042, ISSN: 0733-4680 *

Also Published As

Publication number Publication date
US20090297437A1 (en) 2009-12-03
WO2006063418A2 (fr) 2006-06-22
EP1838354A2 (fr) 2007-10-03

Similar Documents

Publication Publication Date Title
EP1909904A4 (fr) Methodes et appareil pour planifier et pour administrer des traitements de radiotherapie
EP2100614B8 (fr) Anticorps contre PDGFR-alpha pour l'utilisation dans le traitement de tumeurs
BRPI0807012A2 (pt) Uso de inseticidas, método de reduzir ou evitar o efeito fitotóxico de fungicidas, e, agente.
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
WO2005105113A3 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
WO2005046620A3 (fr) Marquages tissulaires d'aspect variable
IL177360A0 (en) 5,6-dialkyl-7-amino-triazolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds
PL1725561T3 (pl) 5,6-Dialkilo-7-aminotriazolopirymidyny, sposób ich wytwarzania i ich zastosowanie do zwalczania szkodliwych grzybów oraz środki zawierające te związki
WO2005096990A3 (fr) Nouvelle modification de protheses medicales
EP1622589A4 (fr) Compositions, cibles, methodes et dispositifs pour le traitement de troubles oculaires et peri-oculaires
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EP4364800A3 (fr) Méthodes de traitement de la sclérose en plaques progressive
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
HK1099273A1 (en) Process for the preparation of 1,1,1,3,3,3-hexafluoropropane and at least one of 1,1,1,2,3,3-hexafluoropropane and 1,1,1,2,3,3,3-heptafluoropropane
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
EP1940377A4 (fr) Compositions analgesiques topiques de n,2,3-trimethyl-2-isopropylbutamide et procedes pour les utiliser
WO2005000208A3 (fr) Therapie combinee pour le traitement des neoplasmes
AU2003281907A1 (en) Collimator and radiation irradiator
EP1792930A4 (fr) Poudre modifiée, composé fluide contenant ladite poudre modifiée, article formé et méthode de production de poudre modifiée
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
WO2006063418A3 (fr) Dispositif radioactif
IL177440A0 (en) 5,6-dialkyl-7-amino-triazolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds
WO2009031890A3 (fr) Particule vectrice à utiliser dans des bio-applications
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
WO2004105696A3 (fr) Therapie combinatoire pour le traitement des neoplasmes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005846349

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005846349

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11721959

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载